Soros Fund Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Soros Fund Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-14,473	Closed	-$98K	–	170
2020 Q2	$98K	Sell	14,473 -78,427	-84%	-$594K	﹤0.01%	139
2020 Q1	$591K	Buy	+92,900	New	+$745K	0.03%	107

Other funds holding CLVS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Soros Fund Management's CLVS Position: Q3 2020 in Review

Soros Fund Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2020, closing a stake of 14,473 shares — an estimated $98K sold.

Soros Fund Management first reported a position in CLVS in Q1 2020 and held it in 2 quarters. The position peaked at $591K in Q1 2020. 169 funds tracked by Wall St. Rank hold CLVS as of Q3 2020.

Soros Fund Management reported no remaining Clovis Oncology, Inc. position as of Q3 2020 after selling out during the quarter.
Soros Fund Management sold 14,473 Clovis Oncology, Inc. shares in Q3 2020, an estimated $98K.
Soros Fund Management first reported a position in Clovis Oncology, Inc. in Q1 2020 and held it in 2 quarters.
Soros Fund Management's Clovis Oncology, Inc. position peaked at $591K in Q1 2020.
169 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2020.

Based on Soros Fund Management's 13F filing for Q3 2020, filed 13 Nov 2020.